Efficacy and safety of anlotinib, a multikinase angiogenesis inhibitor, in combination with epirubicin in preclinical models of soft tissue sarcoma

Efficacy and safety of anlotinib, a multikinase angiogenesis inhibitor, in combination with epirubicin in preclinical models of soft tissue sarcoma

Abstract Background Anlotinib is a novel, orally administered, multitarget receptor tyrosine kinase inhibitor. It functions by inhibiting tumor angiogenesis and proliferative signaling pathways. In this study, we aimed to investigate the efficacy and safety of anlotinib plus epirubicin in a sarcoma...

Full description

Bibliographic Details
Main Authors: Zhi‐Ming Wang, Shi‐Long Zhang, Hua Yang, Rong‐Yuan Zhuang, Xi Guo, Han‐Xing Tong, Yong Zhang, Wei‐Qi Lu, Yu‐Hong Zhou
Format: Article
Language:English
Published: Wiley 2020-05-01
Series:Cancer Medicine
Subjects:
anlotinib
combination
epirubicin
patient‐derived xenografts
soft tissue sarcoma
tyrosine kinase inhibitor
Online Access:https://doi.org/10.1002/cam4.2941

Internet

https://doi.org/10.1002/cam4.2941

Similar Items